AveXis Inc. (AVXS) Shares Down 2.2%
AveXis Inc. (NASDAQ:AVXS) shares were down 2.2% during mid-day trading on Friday . The company traded as low as $38.31 and last traded at $39.33, with a volume of 219,937 shares changing hands. The stock had previously closed at $40.22.
AVXS has been the topic of a number of recent analyst reports. Goldman Sachs Group Inc. boosted their price target on shares of AveXis from $28.00 to $47.00 and gave the stock a “buy” rating in a research report on Friday, May 13th. Zacks Investment Research upgraded shares of AveXis from a “hold” rating to a “buy” rating and set a $39.00 price target on the stock in a research report on Thursday, May 12th. Chardan Capital restated a “buy” rating and set a $60.00 price target on shares of AveXis in a research report on Monday, May 9th. Jefferies Group downgraded shares of AveXis from a “buy” rating to a “hold” rating and boosted their price target for the stock from $39.00 to $42.00 in a research report on Wednesday, June 22nd. They noted that the move was a valuation call. Finally, Wells Fargo & Co. initiated coverage on shares of AveXis in a research report on Friday, July 15th. They set a “market perform” rating on the stock. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $43.80.
The firm’s market cap is $906.94 million. The company has a 50 day moving average price of $39.94 and a 200-day moving average price of $30.81.
AveXis (NASDAQ:AVXS) last announced its quarterly earnings data on Thursday, May 12th. The company reported ($1.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by $0.89. Analysts predict that AveXis Inc. will post ($3.65) earnings per share for the current fiscal year.
AveXis, Inc, formerly Biolife Cell Bank, Inc, is a clinical-stage gene therapy company. The Company operates through developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.